Emerging studies suggest Retatrutide , a dual stimulator targeting both incretin and another hormone, appears to provide a promising step forward for obesity management . Preliminary human tests have demonstrated impressive reductions in abdominal mass , possibly outperforming current body composition treatments. However , additional assessment is